Dalpiciclib 150mg

DRUG3 trials

Sponsors

West China Hospital, wanghaibo

Conditions

Esophageal Squamous Cell CarcinomaHR Positive HER2 Negative Advanced Breast CancerHead and Neck Squamous Cell Carcinoma

Phase 1

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

RecruitingNCT06109207

West China HospitalHead and Neck Squamous Cell Carcinoma

Start: 2023-10-31End: 2025-10-31Target: 6Updated: 2024-07-23

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

RecruitingNCT06225921

West China HospitalEsophageal Squamous Cell Carcinoma

Start: 2023-12-29End: 2025-01-15Target: 6Updated: 2024-03-06

Phase 2

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

RecruitingNCT07285382

wanghaiboHR Positive HER2 Negative Advanced Breast Cancer

Start: 2025-06-25End: 2028-12-31Target: 120Updated: 2025-12-16